ARMO Biosciences Inc (ARMO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ARMO Biosciences Inc (ARMO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8281
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ARMO Biosciences Inc (ARMO Biosciences) is an immuno-oncology company that develops tumors treatment drugs. Its pipeline drug candidates include AM0010, AM0015, AM0012, AM0003 and AM0001. ARMO Biosciences’s lead immunotherapy AM0010 is along-acting form of recombinant human Interleukin 10 (IL-10). The company’s AM0001, is a monoclonal antibody that activates T cells by blocking the interaction between the checkpoint inhibitors programmed cell death protein-1 and programmed cell death ligand-1. Its pipeline comprises various validated product candidates aimed at treating a variety of cancers in combination with standard of care and emerging immunotherapies. ARMO Biosciences is headquartered in Redwood City, California, the US.

ARMO Biosciences Inc (ARMO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ARMO Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Armo Biosciences Completes Acquisition Of Prevascar Assets Of Renovo For US$0.7 Million 11
Venture Financing 12
ARMO Biosciences Raises USD67 Million in Series C-1 Financing 12
Armo Biosciences Raises USD50 Million in Series C Financing 14
Armo Biosciences Raises USD30 Million in Series B Financing 16
ARMO Biosciences Raises US$20 Million In Series A Financing 18
Licensing Agreements 20
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
ARMO Biosciences Enters into Licensing Agreement with Merck 21
Equity Offering 22
ARMO BioSciences Raises USD128 Million in IPO 22
Acquisition 24
Eli Lilly Acquires ARMO Biosciences for USD1.6 Billion 24
ARMO Biosciences Inc – Key Competitors 26
ARMO Biosciences Inc – Key Employees 27
ARMO Biosciences Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Apr 02, 2018: ARMO BioSciences Reports FY 2017 Financial Results 29
Corporate Communications 30
Nov 28, 2017: ARMO BioSciences Appoints Herb Cross as Chief Financial Officer 30
Jun 28, 2017: ARMO BioSciences Appoints Naiyer A. Rizvi, M.D. to Board of Directors 31
Apr 26, 2017: ARMO BioSciences Appoints Pierre Legault to Board of Directors 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ARMO Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ARMO Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Armo Biosciences Completes Acquisition Of Prevascar Assets Of Renovo For US$0.7 Million 11
ARMO Biosciences Raises USD67 Million in Series C-1 Financing 12
Armo Biosciences Raises USD50 Million in Series C Financing 14
Armo Biosciences Raises USD30 Million in Series B Financing 16
ARMO Biosciences Raises US$20 Million In Series A Financing 18
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
ARMO Biosciences Enters into Licensing Agreement with Merck 21
ARMO BioSciences Raises USD128 Million in IPO 22
Eli Lilly Acquires ARMO Biosciences for USD1.6 Billion 24
ARMO Biosciences Inc, Key Competitors 26
ARMO Biosciences Inc, Key Employees 27

List of Figures
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[ARMO Biosciences Inc (ARMO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Zoltek Corp:企業の戦略的SWOT分析
    Zoltek Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Kuwait Petroleum International Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Kuwait Petroleum International Ltd (KPI), a subsidiary of Kuwait Petroleum Corporation, is a downstream energy company. It carries out refining of crude oil, production and marketing of refined petroleum products. The company operates refinery in Milazzo, Italy, and has retail service statio …
  • InviCRO LLC:医療機器:M&Aディール及び事業提携情報
    Summary InviCRO LLC (InviCRO) a subsidiary of Konica Minolta Inc, is a provider of image informatics, engineering and operational services in translational drug discovery and development. The company developed VivoQuant, a DICOM compliant post-processing suite for image data combining fundamental vi …
  • Johnson & Johnson:企業の戦略・SWOT・財務情報
    Johnson & Johnson - Strategy, SWOT and Corporate Finance Report Summary Johnson & Johnson - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Sumitomo Realty & Development Co., Ltd.:企業の戦略・SWOT・財務情報
    Sumitomo Realty & Development Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Realty & Development Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Immatics Biotechnologies GmbH:企業の戦略的SWOT分析
    Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Biodesix Inc:医療機器:M&Aディール及び事業提携情報
    Summary Biodesix Inc (Biodesix) is a molecular diagnostics company which discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests in oncology for patients and doctors to enable precision medicine. These tests are used for early detection of diseases, diagnosis a …
  • PT Perusahaan Gas Negara (Persero) Tbk (PGAS):企業の財務・戦略的SWOT分析
    PT Perusahaan Gas Negara (Persero) Tbk (PGAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Ansvar Insurance Limited
    Ansvar Insurance Limited - Strategy, SWOT and Corporate Finance Report Summary Ansvar Insurance Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Taerim Packaging Co., Ltd:企業の戦略・SWOT・財務情報
    Taerim Packaging Co., Ltd - Strategy, SWOT and Corporate Finance Report Summary Taerim Packaging Co., Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Brokk AB:企業の戦略的SWOT分析
    Brokk AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Genetic Analysis AS:医療機器:M&Aディール及び事業提携情報
    Summary Genetic Analysis AS (Genetic Analysis) is a molecular diagnostic company that mapping of microbiota by utilizing the GA-map technology to develop IVD tests in various diseases. The company develops gene-based routine tests for the mapping and diagnosis of diseases related to dysbiosis and ba …
  • Karolinska Development AB (KDEV):企業の財務・戦略的SWOT分析
    Summary Karolinska Development AB (Karolinska Development) is a life sciences investment company that develops innovations from science into commercial products. The company invests in start up's and growth of the pharmaceutical, medical device and biotechnology companies that develop specialty care …
  • Centrica Plc (CNA):電力:M&Aディール及び事業提携情報
    Summary Centrica Plc (Centrica) is an integrated energy company. It carries out electricity generation through and combined cycle gas turbine (CCGT) power stations, and nuclear power plants through its stake in EDF Energy Nuclear Generation. Centrica secures and supply gas and electricity to homes a …
  • Planet Gas Ltd (PGS):石油・ガス:M&Aディール及び事業提携情報
    Summary Planet Gas Ltd (Planet Gas) is an upstream oil and gas company that offers acquisition, exploration, production and development of oil and gas properties in the US. The company holds interests in conventional and unconventional oil and gas projects in Australia. It projects explores for coal …
  • Banca Monte dei Paschi di Siena SpA:企業のM&A・事業提携・投資動向
    Banca Monte dei Paschi di Siena SpA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Banca Monte dei Paschi di Siena SpA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on …
  • National Fuel Gas Co (NFG):企業の財務・戦略的SWOT分析
    National Fuel Gas Co (NFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Medworxx Inc-医療機器分野:企業M&A・提携分析
    Summary Medworxx Inc (Medworxx), a subsidiary of Aptean Inc is an information technology solution provider that offers software solutions for patient flow, compliance, and education. The company’s software products include patient throughput review software, clinical criteria software, forms and ass …
  • Biosceptre International Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Biosceptre International Ltd (Biosceptre) is a biotechnology company that develops antibody technologies for applications in the diagnosis and treatment of cancer. The company develops imaging technologies to detect and monitor cancer. Its diagnostic products are used for the detection of va …
  • Aegerion Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Aegerion Pharmaceuticals Inc (Aegerion) is a pharmaceutical company that develops therapies for patients with debilitating often fatal and rare diseases. The company provides therapeutics to treat severe inherited lipid disorders. Its therapeutic focus comprise homozygous familial hyperchole …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆